Monte Rosa Therapeutics, Inc. (GLUE): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLUE Stock Price Chart Interactive Chart >
GLUE Price/Volume Stats
| Current price | $7.45 | 52-week high | $15.54 |
| Prev. close | $6.83 | 52-week low | $6.05 |
| Day low | $6.81 | Volume | 186,600 |
| Day high | $7.60 | Avg. volume | 132,433 |
| 50-day MA | $8.17 | Dividend yield | N/A |
| 200-day MA | $8.86 | Market Cap | 360.57M |
Monte Rosa Therapeutics, Inc. (GLUE) Company Bio
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.
Latest GLUE News From Around the Web
Below are the latest news stories about MONTE ROSA THERAPEUTICS INC that investors may wish to consider to help them evaluate GLUE as an investment opportunity.
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionDisclosure of initial data from Phase 1 arm of ongoing Phase 1/2 clinical trial evaluating MRT-2359 expected in second half of 2023Nomination of multiple additional development candidates anticipated in 2023Company to present pipeline and corporate updates at 41st Annual J.P. Morgan Healthcare Conference on Wednes |
Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT. |
Alphabet Inc (GOOGL) Investment Portfolio: Top 15 CompaniesIn this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […] |
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors – |
GLUE Price Returns
| 1-mo | 1.78% |
| 3-mo | -14.17% |
| 6-mo | -12.15% |
| 1-year | -30.57% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -2.10% |
| 2022 | -62.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...